- cafead Mar 29, 2023 at 10:02: AM
via The FDA has lifted a partial clinical hold on Blueprint Medicines’ early-stage cancer drug, clearing the way for the biotech to dose new patients.
article source
article source
-
Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page
FDA lifts partial hold on Blueprint's CDK2 inhibitor
- Thread starter cafead
- Start date
<
Similar threads